# Medicare and GLP-1s: the $50 Bridge That Opened in July

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-16 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/medicare-glp1-bridge

> From July 1, 2026, a temporary program sitting outside Part D has let Medicare beneficiaries get some GLP-1 drugs for weight management at $50 a month. Eligibility, covered drugs, and the Zepbound restriction most people miss.

## Key points

- $50 monthly copay, July 1, 2026 to December 31, 2027, nationwide including all US territories.
- It runs OUTSIDE the Part D benefit because the statute barring Medicare from covering weight-loss drugs has not changed.
- Eligibility is judged at the time GLP-1 therapy STARTED. Losing weight since does not disqualify you.
- Zepbound is covered as the KwikPen ONLY; single-dose vials and pens are excluded.

The answer to “does Medicare cover Wegovy” changed on **July 1, 2026**, and most pages answering it are still describing the old rules. Under a temporary arrangement called the Medicare GLP-1 Bridge, several GLP-1 drugs prescribed for weight are now paid for, and eligible beneficiaries pay a flat **$50 a month**.[1]

It is not a permanent benefit, and it is not Part D coverage in the ordinary sense. It deliberately runs outside the Part D payment structure, because the law that bars Medicare from covering weight-loss drugs has not changed.[2] It runs until **December 31, 2027**. That end date is itself an extension: CMS lengthened the Bridge because the BALANCE model, meant to carry GLP-1 coverage into Part D, will not launch in Medicare in 2027.[2]

## Why a bridge, and not just coverage

Medicare has been barred by statute from covering drugs used for weight loss. That is why a drug like Wegovy could be covered under Part D *for cardiovascular risk reduction* (an approved indication that is not weight loss) while the same drug for the same person, prescribed for weight, was not covered.

The Bridge is how CMS works around that. It is a short-term demonstration operating outside the Part D benefit, so it can reach a weight-management indication the benefit itself cannot. The corollary matters. If you already get a GLP-1 covered under your Part D benefit for an indication Part D allows, you stay there, and the Bridge is not for you.

## Who qualifies

You must be 18 or older and have Medicare drug coverage, and you must have met **one** of the following *at the time GLP-1 therapy started*, not necessarily today.[1]

*Medicare GLP-1 Bridge clinical criteria*

| BMI at start of therapy | Additional condition required |
| --- | --- |
| **35 or higher** | None |
| **30 or higher** | One of: kidney disease at chronic stage 3a or worse; hypertension that is not under control; or diastolic heart failure, the preserved-ejection-fraction type |
| **27 or higher** | One of: [prediabetes](https://glpwatchdog.org/research/glp1-for-prediabetes); a past stroke or myocardial infarction; or peripheral artery disease that is causing symptoms |

Three diagnoses shut the door regardless of BMI: **type 2 diabetes, moderate-to-severe sleep apnea and fatty liver disease**. Medicare.gov gives the reason in a parenthesis: a Part D plan may already cover a GLP-1 for those.[1] [Humana’s Medicare page](https://glpwatchdog.org/insurance/humana) draws the same line: standard Part D plans do not cover GLP-1 drugs only for weight loss, though Part D “may cover” Ozempic and Wegovy prescribed for diabetes or cardiovascular disease.[4]

> **“At the time therapy started” is the phrase that matters.** CMS gives an example: treatment began in September 2024 at a body mass index of 37, which was down to 34 by the day the authorization request was filed. The prescriber attests to the earlier figure, so the qualifying number is the one you had *before* the drug worked. Losing weight on the drug does not disqualify you.[2]

The plan types covered are broad: standalone drug plans (PDP), Medicare Advantage plans with drug coverage (MA-PD, including HMO, HMOPOS and local or regional PPO), Special Needs Plans, group waiver plans run for an employer or a union (EGWPs), and LI NET. It is nationwide, including all states and US territories.[1]

## Which drugs, and the restriction people will miss

*Covered under the Bridge from July 1, 2026*

| Drug | Form |
| --- | --- |
| Foundayo | Tablet |
| Wegovy | Injection or tablet |
| Zepbound | **KwikPen only** — single-dose vials and pens are *not* covered |

> **The Zepbound restriction is the detail most likely to cost someone a filled prescription.** Zepbound is widely dispensed as [single-dose vials](https://glpwatchdog.org/research/zepbound-vials-and-syringes), particularly through the manufacturer's direct-pay program, and those are excluded. If Zepbound is your drug, the prescription has to specify the KwikPen. Raise this before the prescription is written, not at the pharmacy counter.

Mounjaro and Ozempic are not on the list. That follows from the design: both carry diabetes indications, and a diabetes prescription is already a Part D matter rather than a Bridge one.

## How to get it

1. **Confirm you have Part D drug coverage** of one of the qualifying plan types.
2. **Check the criteria against when you started**, not against today’s numbers, and gather what documents that.
3. **A covered drug is prescribed and sent to a pharmacy.** If prior authorization is requested, the prescriber completes it. Some online prescribers accept Medicare, [LifeMD](https://glpwatchdog.org/reviews/lifemd) among them, so ask whether yours will handle the Bridge request before you book. Our [list of sellers that take insurance](https://glpwatchdog.org/best/glp1-providers-that-take-insurance) is a place to start, but ask about Medicare by name. In 2026 CMS uses a single central processor for authorization, claims and pharmacy payment.[2] Your own plan does not approve the request, as [Aetna tells its Medicare members](https://glpwatchdog.org/research/does-aetna-cover-zepbound-and-wegovy). Once approved, the authorization holds for refills and dose changes through December 31, 2027, unless you switch to a different GLP-1.[1]
4. **Your provider certifies the lifestyle requirement.** They must confirm you are using the drug as part of a program focused on diet and exercise. This is a condition of the program, not a formality.
5. **Bring your Medicare Number.** The pharmacy may ask for it, or for the last four digits of your Social Security Number.[1]

> **If you are turned down**, the same logic applies as with any coverage decision: get the reason in writing, establish whether you missed a criterion or fall outside the program entirely, and fix the specific gap. Our guide to [getting a GLP-1 covered](https://glpwatchdog.org/research/how-to-get-a-glp1-covered-by-insurance) walks that through, and the [prior-authorization letter generator](https://glpwatchdog.org/tools/glp1-prior-auth-letter-generator) assembles a request for your prescriber to review.

## $50 against the cash market

For anyone who qualifies, $50 a month undercuts the entire cash market, including the [TrumpRx prices](https://glpwatchdog.org/research/trumprx-glp1-prices). When we wrote this in August 2026, across the 481 compounded semaglutide prices in this register the cheapest was $65 and the median $189.99; across 435 tirzepatide prices the cheapest was $83 and the median $258. Nothing in the compounded market reached $50. The bigger difference, though, is that the Bridge supplies the approved product rather than a compounded preparation.

It ends on December 31, 2027, and CMS describes it as short-term. What follows is not settled on the current public record, so treat the $50 as a window rather than a permanent floor. Our [cash-market guide](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) covers what the alternative costs today, and [Foundayo cost](https://glpwatchdog.org/research/foundayo-cost) sets the $50 against Lilly’s self-pay ladder.

## Common questions

## Frequently asked questions

### Does Medicare cover Wegovy?

Yes, in two separate ways, and the distinction matters. Part D plans may cover Wegovy for cardiovascular risk reduction, because that is an approved indication that is not weight loss. And since July 1, 2026 the Medicare GLP-1 Bridge provides access for weight management at a $50 monthly copay for people who meet its criteria. The Bridge operates outside the Part D benefit because Medicare remains statutorily barred from covering drugs used for weight loss.

### How much does it cost?

$50 a month through the Bridge, with prior authorization required.

### How long does the program last?

July 1, 2026 to December 31, 2027. CMS extended it to that date because the BALANCE model will not launch in Medicare in 2027, and it still describes the Bridge as a short-term demonstration. What replaces it is not settled on the public record, so it is a window rather than a permanent arrangement.

### Is Zepbound covered?

Only the KwikPen. Single-dose Zepbound vials and pens are excluded, which is easy to miss and is the kind of detail that stops a prescription being filled. If Zepbound is your drug, make sure the prescription specifies the KwikPen.

### Can I use the Bridge if I have type 2 diabetes?

No. Medicare.gov lists type 2 diabetes, moderate-to-severe sleep apnea and fatty liver disease as exclusions, because a Part D plan may already cover a GLP-1 for those conditions. Ask your Part D plan instead.

### What if I have already lost weight since starting?

The criteria are assessed at the time GLP-1 therapy began, not at the time you apply. CMS's own example is someone who started at BMI 37 and is at 34 by the prior-authorization request; the prescriber attests to the figure at initiation. Succeeding does not disqualify you.

### What if I already get a GLP-1 through my Part D plan?

Then you stay there. The Bridge is specifically for the weight-management indication that the Part D benefit cannot cover. If your prescription is for an indication Part D already allows, such as diabetes or Wegovy for cardiovascular risk, you continue getting it that way.

### Are Mounjaro and Ozempic covered by the Bridge?

No. The covered list is Foundayo, Wegovy, and the Zepbound KwikPen. Mounjaro and Ozempic carry diabetes indications, and a diabetes prescription is already a Part D question rather than a Bridge one.

## References

1. Centers for Medicare & Medicaid Services Weight loss drugs — Medicare GLP-1 Bridge coverage, eligibility, covered drugs and costs. Medicare.gov. 2026. https://www.medicare.gov/coverage/weight-loss-drugs
2. Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge — Information for Providers. CMS. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
3. Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge — Information for Part D Plans. CMS. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
4. Humana Does Medicare cover GLP-1 weight loss drugs? (updated June 8, 2026). humana.com. 2026. https://www.humana.com/medicare/medicare-resources/does-medicare-cover-weight-loss-drugs

---

Cite as: GLP Watchdog, Nora Bissett, "Medicare and GLP-1s: the $50 Bridge That Opened in July", published 2026-08-16, updated 2026-11-01. https://glpwatchdog.org/research/medicare-glp1-bridge

Canonical HTML page: https://glpwatchdog.org/research/medicare-glp1-bridge

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.